GlaxoSmithKline PLC said today that it is seeking regulatory approval in the United States and Europe to expand its cancer drug Tykerb for use as a first-line treatment of advanced breast cancer.

GlaxoSmithKline PLC said today that it is seeking regulatory approval in the United States and Europe to expand its cancer drug Tykerb for use as a first-line treatment of advanced breast cancer.